Gastroenterology and renal diseases

Česká verzia

Authors: V. Teplan ^1–4; O. Marečková ⁵; M. Lukáš ^1,2
Authors place of work: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha ¹; 1. LF UK, Praha ²; Subkatedra nefrologie, Institut postgraduálního vzdělávání ve zdravotnictví, Praha ³; Katedra interních oborů, LF OU, Ostrava 5 Klinika nefrologie, Transplantcentrum, IKEM, Praha ⁴
Published in the journal: Gastroent Hepatol 2018; 72(1): 50-57
Category: Chapters from internal medicine: Review Article
doi: https://doi.org/10.14735/amgh201850

Summary

Gastrointestinal and renal diseases may occur simultaneously. Urinary complications have been reported in up to 25% of patients with inflammatory bowel disease (IBD), and include ureteral obstruction, enterovesical fistulas, lower and upper urinary tract infection and kidney stones as the most common manifestations. Furthermore, immunology-based kidney diseases are more frequently found in these patients. Membranous glomerulopathy may be associated with bowel tumours. Conversely, chronic renal failure mainly in long-term dialysed patients leads to chronic damage of the upper and lower gastrointestinal tract along with bleeding, perforation, pancreatic irritation and diarrhoea. Inadequate management of renal failure leads to vomiting and diarrhoea. Water and mineral disturbances, frequently accompanied by hypokalaemia, due to infectious and non-infectious bowel disease can be linked to acute kidney injury or failure, and are usually reversible after recovery of water and minerals to normal levels. A higher prevalence of bowel tumours, mainly lymphomas, is found in patients who undergo kidney transplantation. Use of biologics stabilises patients with IBD who have undergone transplant and are on long-term immunosuppressive management.

Key words:
kidney – inflammatory bowel diseases – urolithiasis – infection – bleeding – tumours

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
29. 1. 2018

Accepted:
1. 2. 2018

Zdroje

1. Marečková O. Poruchy gastrointestinálního traktu u chorob ledvin. In: Teplan V. Metabolismus a ledviny. Praha: Grada Avicenum 2000: 147–157.

2. Ritz E. Gastrointestinal disease and the kidney. In: Davison AM, Cameron JS, Grunfeld JP (eds) et al. Oxford textbook clinical nephrology. Oxford: Oxford University Press 1998: 2733–2735.

3. Bortlík M. Vývoj léčby idiopatických střevních zánětů v posledních 20 letech. Gastroent Hepatol 2015; 69 (4): 341–350.

4. Ganji-Arjenaki M, Nasri H, Rafieian-Kopael M. Nephrolothiasis as a common urinary manifestation of inflammatory bowel disease; a clinical review and meta-analysis. J Nephropatol 2017; 6 (3): 264–269. doi: 10.15171/jnp.2017.42.

5. Ben-Ani H, Ginesin Y, Behar DM et al. Diagnosis and treatment of urinary tract complication in Crohn‘s disease: an experience over 15 years. Can J Gastroenterol 2002; 16 (4): 225–229.

6. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn‘s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55 (5): 401–412.

7. Kavanagh D, Neary P, Dodd J et al. Diagnosis and treatment of enterovesical fistulae. Colorectal Dis 2005; 7 (3): 286–291.

8. Ferguson GG, Lee EW, Hunt SR et al. Management of the bladder during surgical treatment of enterovesical fistulas from benign bowel disease. J Am Coll Surg 2008; 207 (4): 569–572. doi: 10.1016/j.jamcollsurg.2008.05.006.

9. Teplan V, Lukáš M. Urolithiasis in patients with inflammatory bowel disease. Gastroent Hepatol 2015; 69 (6): 561–569. doi: 10.14735/amgh2015561

10. Poon KS, Gilks CB, Masterson JS. Metastatis Crohn‘s disease involving the genitalia. J Urol 2002; 167 (6): 2541–2542.

11. Robijn S, Hoppe B et al. Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80 (11): 1146–1158. doi: 10.1038/ki.2011.287.

12. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31 (4): 927–949.

13. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142 (1): 46–54. doi: 10.1053/j.gastro.2011.10.001.

14. Molina-Pérez M, González-Reimers E, Santolaria-Fernándes F et al. Rapidly progressive glomerulonephritis and inflammatory bowel disease. Dis Colon Rectum 1995; 38 (9): 1006–1007.

15. Shaer AJ, Stewart LR, Cheek DE et al. IgA antiglomerular basement membrane nephritis associated with Crohn‘s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis May 2003; 41 (5): 1097–1109.

16. Ebert EC, Nagar M. Gastroinstestinal manifestation of amyloidosis. Am Gastroenterol 2008; 103 (3): 776–787.

17. Katsanos K, Tsianos EV. The kidneys in inflammatory bowel disease. Ann Gastroenterol 2002; 15: 41–52.

18. Serra I, Oller B, Mañosa M et al. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis 2010; 4 (3): 269–274. doi: 10.1016/j.crohns.2009.11.009.

19. Basturk T, Ozagari A, Ozturk T et al. Crohn‘s disease and secondary amyloidosis: early complication? A case report and review of the literature. J Ren Care 2009; 35 (3): 147–150. doi: 10.1111/j.1755-6686.2009.00106.x.

20. Peeters AJ, van den Wall Bake AW, Daha MR et al. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis 1990; 49 (8): 638–640.

21. Lukáš M, Bortlík M, Novotný A et al. Nefrotoxicita mesalazinu při dlouhodobé léčbě ulcerozní kolitidy a Crohnovy nemoci. Čes a Slov Gastroent 1999; 53 (5): 135–139.

22. Oikonomou KA, Kapsoritakis AN, Stefanidis I et al. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract 2011; 119 (2): 89–94. doi: 10.1159/000326682.

23. Tada Y, Ishihara S, Ito T et al. Successful use of maintenanace Infliximab for nephropathy in patients with secondary amyloidosis complicating Crohn‘s disease. Intern Med 2013; 52 (17): 1899–1102.

24. Chiba M, Tsuda S, Tsuji Tet al. Crohn disease successfully treated with Infliximab in a patient receiving hemodialysis. Medicine (Baltimore) 2014; 93 (7): e54. doi: 10.1097/MD.000000 0000000054.

25. Webb TN, Griffiths H, Miyashita Y et al. Atypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumab. Int J Med Pharm Case Reports 2015; 4 (5): 105–112.

26. Schnitzler F, Friedrich M, Stallhofer J et al. Solid organ transplantation in patients with inflammatory bowel disease (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort. PLoS One 2015; 10 (8): e0135807. doi: 10.1371/journal.pone.0135807.

27. Pittman ME, Jessurun J, Yantiss RK. Differentiating posttransplant inflammatory bowel disease and other colitides in renal transplant patients. Am J Surg Pathol 2017; 41 (12): 1666–1674. doi: 10.1097/PAS.0000000000000921.

28. Alcázar Arroyo A. Electrolyte and acid-base balance disorders in advanced chronic kidney disease. Nefrologia 2008; 28 (Suppl 3): 87–93.

29. Flam B, Sackey P, Berge A et al. Diarrhea-associated hemolytic uremic syndrome with severe neurological manifestations treated with IgG depletion through immunoadsorption. J Nephrol 2016; 29 (5): 711–714. doi: 10.1007/ s40620-016-0294-5.

30. Primas C, Novacek G, Schweiger K et al. Renal insufficiency in IBD – prevalence and possible pathogenetic aspects. J Crohns Colitis 2013; 7 (12): 630–634. doi: 10.1016/j.crohns.2013.05.001.

31. Teplan V. Akutní poškození a selhání ledvin v klinické medicíně. Praha: Grada Publishing: 2010.

32. Lazarus JM, Denker BM, Owen WF. Management of the patient with renal failure: gastrointestinal abnormalities. In: Brenner BM (ed). The Kidney. Saunders Company 1996: 2460–2463.

33. Doherty CC. Effects of chronic renal failure on gastrointestinal tract structure and function. In: Davison AM, Cameron JS, Grunfeld JP et al. Oxford textbook clinical nephrology. Oxford: Oxford University Press 1998: 1919–1924.

34. Akmal M, Sawelson S, Karubian F et al. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 1994; 42 (3): 198–202.

35. Davenport A, Shallcross TM, Crabtree JE et al. Prevalence of Helicobacter pylori in patients with end stage renal failure and renal transplant recipients. Nephron 1991; 59 (4): 597–601.

36. Hwang HS, Song YM, Kim EO et al. Decisive indicator for gastrointestinal workup in anemic patients with nondialysis chronic kidney disease. Int J Med Sci 2012; 9 (8): 634–641. doi: 10.7150/ijms.4969.

37. Gougol A, Dugum M, Dudekula A. Clinical outcomes of isolated renal failure compared to other forms of organ failure in patients with severe acute pancreatitis. World J Gastroenterol 2017; 23 (29): 5431–5437. doi: 10.3748/wjg.v23.i29.5431.

38. Badalamenti S, DeFazio C, Castelnovo C et al. High prevalence of silent gallstone disease in dialysis patients. Nephron 1994; 66 (2): 225–227.

39. Marečková O, Skála I, Mareček Z et al. Bile composition in patients with chronic renal insufficiency. Nephrol Dial Transplant 1990; 5: 423–425.

40. Benoit G, Moukarzel M, Verdelli G et al. Gastrointestinal complications in renal transplantation. Transplant Int 1993; 6 (1): 45–49.

41. McDonald GB, Rees GM. Approach to gastrointestinal problems in the immunocompromised patient. In: Yamada T (ed). Textbook of gastroenterology. Philadelphia: Lippincott 1995: 988–1022.

42. Blohme I. Gastroduodenal bleeding after renal transplantation. Scand J Urol Nephrol 1975; 29: 21–23.

43. Fang JT, Huang CC, Lai MK et al. Acute pancreatitis after renal transplantation. Transplant Proc 1994; 26 (4): 1993–1994.

44. Bardaxoglou E, Maddern G, Ruso L et al. Gastrointestinal surgical emergencies following kidney transplantation. Transpl Int 1993; 6 (3): 148–152.

45. Toogood GJ, Gillespie PH, Gujral E. Cytomegalovirus infection and colonic perforation in renal transplant patients. Transpl Int 1996; 9 (3): 248–251.

46. Lee JT, Dunn TB, Sirany AM. Colorectal surgery after kidney transplantation: characteristics of early vs. late posttransplant interventions. J Gastrointest Surg 2014; 18 (7): 1299–1305. doi: 10.1007/s11605-014-2534-0.

47. Graham SM, Flowers JL, Schweitzer E et al. The utility of prophylactic laparoscopic cholecystectomy in transplant candidates. Am J Surgery 1995; 169 (1): 44–49.